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Functions of Purinergic Receptors
Eren Sarikaya
Abstract
Purinergic receptors, also known as purinoceptors, are a family of plasma mem-
brane molecules found in many mammalian tissues. Purinergic receptors are trans-
membrane receptors consisting of two main categories. P1 receptors are stimulated 
by adenosine. Those that respond to extracellular nucleotides (ATP, ADP, UTP and 
UDP) are P2 receptors. The P2X receptors are ligand-gated ion channels. The P1 and 
P2Y receptors are bound to the G protein. Both of these metabotropic receptors are 
distinguished by taking into account their reactivity to specific activators. P1 and 
P2Y receptors are widely distributed in the brain, heart, kidneys and adipose tissue.
Keywords: purinergic receptors, P1, P2, ATP, UTP
1. Introduction
1.1 The possible physiological sources of nucleotides and nucleosides
ATP and other described nucleotides treat both metabotropic (P2Y) and iono-
trophic (P2X) receptors. P2X receptors subunits (P2X1–P2X7) form ligand-gated 
cation channels, like homomultimers or heteromultimers. P2X3 subunits contribute 
to the ion permeability pathway by joining the fields of each subunit. P2X3R has the 
lowest recorded relative Ca2+ permeability of the family. P2X7, in addition to cation 
channels, is associated to contain large cytolytic pores; that are found in macro-
phages and brain microglial cells. P2Y receptors can activate or inhibit adenylate 
cyclase according to the subtype and consequently the type of coupled G protein. 
Adenylate cyclase and especially for the Ca2+ channel inhibition appears. P2Y 
receptors form as subset of G-protein-linked receptors; most mate to phospholipase 
C via the G protein, but inhibition of adenylate cyclase and N-type Ca2+ channels 
and activation of K+ channels also occurs. The expressed P2Y receptors are gener-
ally pharmacologically distinguished by the rank order of the agonists; some prefer 
pyrimidine to purine. Several P2Y receptors have a very common tissue distribution 
[1]. Molecular structures of ATP and BzATP are shown in Figure 1.
Adenine nucleotides inhibit isoproterenol and forskolin-induced cyclic AMP 
accumulation in C6-2B rat glioma cells. This inhibition occurs in the presence of a 
phosphodiesterase inhibitor. Adenine nucleotides did not cause effects in measure-
ments of the direct phosphodiesterase activity in intact cells. Pretreatment of C6-2B 
glioma cells with pertussis toxin blocked the inhibitory effects of P2Y-purinergic 
receptor agonists. A number of ATP and ADP analogs produced a rank potency 
order (2-methylthioadenosine 5′-triphosphate> or = 2-methylthioadenosine 
5′-diphosphate > adenosine 5′-O-(2-thiodiphosphate) > 2-chloro-adenosine 
ADP = adenosine 5′-O-(3-thio- triphosphate) > ATP > UTP) expected from a P2Y-
purinergic receptor activation; and the P2X-purinergic receptor agonists, alpha, 
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beta-methyleneadenosine 5′-triphosphate and beta, gamma-methylene-adenosine 
5′-triphosphate had no effect. Phospholipase C activity occurs in response to 
P2-purinergic receptor activation in many target tissues, therefore the effects of 
P2Y receptor agonists on inositol phosphate accumulation were measured in C6-2B 
cells. No evidence was found for the regulation of P2Y-purinergic receptor mediated 
by inositol lipid metabolism under conditions where the activation of muscarinic 
cholinergic receptor or AIF4 increased the inositol phosphate accumulation. These 
results indicate that a P2-purinergic receptor subtype with different signaling char-
acteristics is present on the C6-2B rat glioma cells. Although this receptor expresses 
the general pharmacological properties of a phospholipase C-linked P2Y-purinergic 
receptor, it may represent a unique receptor subtype because it inhibits adenylyl 
cyclase [3].
Purines were thought to be limited to the intracellular compartment in which 
they were used for energy processing, nucleic acid synthesis and a large number of 
biochemical reactions. Karl Lohmann isolated ATP, which is the key intracellular 
energy currency, in 1929 [4]. However, adenosine and adenosine triphosphate (i) 
are abundant biochemical components of the tumor microenvironment, (ii) are 
strong modulators of immune cell responses and cytokine release, and (iii) are 
key players in host-tumor interaction. In addition, both nucleotides directly affect 
tumor cell growth. Adenosine is a potent immunosuppressant (mainly effective 
at A2A receptors) and a cell growth modulator (mainly effective at A3 receptors). 
ATP is a proinflammatory agent (effective in P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 
and at P2X4 and P2X7 receptors), an immunosuppressant (effective in P2Y11) and 
a growth promoter (effective in P2Y1, P2Y2 and P2X7). This complex signaling 
network produces a number of inhibitory and stimulating responses that affect 
immune cell function, tumor growth and metastatic spread.
Purinergic receptors, represented by many families, are the most abundant 
receptors in living organisms, possibly occurring in the early stages of evolution. 
Purinergic signaling in peripheral and central nervous systems is a rapidly expand-
ing field. Examination of these receptors makes it possible to develop therapeutic 
strategies for these disorders with novel mechanisms of action, including purulent, 
pathogenic conditions, including pain, trauma, ischemia, epilepsy, migraine, 
psychiatric disorders and drug dependence [5].
In micromolar/nanomolar concentrations, extracellular adenosine triphosphate 
(ATP) has been shown to produce significant functional changes in a wide variety 
of normal and transformed cell types. Although ATP can be specifically released 
Figure 1. 
Molecular structures of ATP and BzATP [2].
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from the cytosol of damaged cells, it is also packaged in some exocytotic vesicles/
granules containing conventional neurotransmitters and hormones. Various bio-
logical responses to ATP are mediated by various P2-purinergic cell surface recep-
tors activated upon binding of ATP and other nucleotides. Recent physiological, 
biochemical and pharmacological studies have shown that there are multiple types 
of ATP receptor subtypes. These include: (1) G-protein-bound ATP receptors that 
induce inositol phospholipid hydrolysis, Ca2 + mobilization and activation of protein 
kinase C; (2) ATP receptors that directly activate non-selective cation channels in 
plasma membranes of various cell types and (3) ATP receptors capable of producing 
cytotoxic or activation responses in T lymphocytes and other immune effector cells 
by rapid induction of surface membrane pores permeable to ions and endogenous 
metabolites (with molecular weights until 900 Da). In addition to these functional 
criteria, these default ATP receptor subtypes can be pharmacologically distinguished 
by characteristic potency for various structurally modified ATP analogs [6].
Intracellular nucleotides play a fundamental and ubiquitous role in energy 
metabolism, nucleic acid synthesis and enzyme regulation. It is widely understood 
that extracellular nucleotides and nucleosides carry out important biological actions 
in many tissues and cells [7]. GLUTs (facilitate transport of glucose into the cells), 
SGLTs (facilitate the re-absorption of glucose back into circulation) and KATP 
(ATP-sensitive potassium channels) metabolic sensors play an important role in 
glucose homeostasis and metabolism in the body and in many specific organs (e.g., 
intestine, pancreas, heart, skeletal muscle and brain) [8].
KATP bind metabolic signals to cell excitability and play an important role 
in many tissues, including regulation of insulin secretion, control of vascular 
tone and protection of neurons and muscles from ischemia. KATP channels are 
octameric complexes consisting of four sulfonylurea receptors (SUR.x) and 
four inwardly rectifying potassium channels (Kir6.x). They are regulated by 
intracellular ATP and ADP. While ATP inhibits channel activity, ADP antago-
nizes the inhibitory effect of ATP in the presence of Mg2+ and stimulates the 
channel activity. These gate properties are essential for this channel to detect 
metabolic changes in cells. Thus, in pancreatic β cells, the [ATP]/[ADP] ratio 
increases in response to blood glucose levels augment, leading to closure of 
the KATP channel, membrane depolarization, activation of voltage-gated Ca2+ 
channels and insulin release. However, when the blood glucose levels are low, the 
[ATP]/[ADP] ratio decreases, KATP channels are opened and insulin secretion 
decreases [9].
The catastrophic channels in the pancreas are activated as follows; in the 
event of β-cell glucose level is increased, the intracellular ratio of ATP to ADP 
also increases, leading to closure of the KATP channel, depolarization of cells and 
insulin release [10].
The P-sensitive K′(K + [ATP]) stream is thought to be regulated by GTP-binding 
proteins (G proteins), but the pathways combining the receptor, G protein and 
channel are not identified. The regulation of tolbutamide-sensitive K′[ATP] cur-
rent in neonatal rat ventricular myocytes is determined. Activated ATP-sensitive 
K + (K + [ATP]) channels are present in cells when intracellular ATP levels decrease. 
Intracellular ATP levels are found when intracellular ATP levels are reduced in the 
cell, intracellular skeletal muscle, brain and pancreas. Little is known about the func-
tion of K + [ATP] channels in heart cells, although their important role in controlling 
insulin secretion from pancreatic P-cells has been well established. When pharma-
cologically activated, these channels greatly reduce the duration of action potential 
and have been proposed to be responsible for the shortening of action potential in 
metabolically dangerous ischemic muscles. However, the ATP concentration in the 
metabolically blocked caste remains above the level, which prevents the channels in 
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the excised membrane patches. A possible explanation for this discrepancy is that the 
ATP sensitivity of the channels can be modulated by intracellular mechanisms [11].
ATP-responsive K+ channels, called KATP channels, provide a link between cel-
lular metabolism and membrane electrical activity in various tissues. Channel iso-
forms are targets for compounds that stimulate and inhibit their activity resulting 
in membrane hyperpolarization and depolarization, respectively. Vascular smooth 
muscle and stimulating insulin secretion loosening are examples for these situations 
above [12]. Adenosine agonists and the openers of the ATP-sensitive potassium 
(KATP) channel were reported to limit infarct size (IS) [13]. ATP-sensitive potas-
sium (KATP) channels are well defined in the heart, skeleton and smooth muscle, 
pancreatic cells, pituitary, central and peripheral nervous system both electrophysi-
ologically and pharmacologically. The activities and hence the various cellular 
functions are controlled by the cellular metabolism. In general, the changes in ATP 
(causing channel closure) and in MgADP (channel activating) are believed to have 
dual metabolism to channel activity 6. It is described that the cellular localization 
of two mRNA transcripts that is expected to generate ATP-sensitive K+ channels 
in the murine brain. There is evidence that the KATP channel in pancreatic cells is 
composed of a Kir6.2 and a complex of SUR1 subunits. KATP channels with similar 
characteristics (type I) have been described in various neurons, including those 
with brain cortex, basic nigra, caudate, and hippocampus [14].
Almost all tumor cells and all immune cells express plasma membrane receptors 
for extracellular nucleosides (adenosine) and nucleotides (ATP, ADP, UTP, UDP 
and sugar UDP). The tumor microenvironment is characterized by an unusually 
high concentration of ATP and adenosine. Adenosine is an important determinant 
of the immunosuppressive tumor environment. Serial hydrolysis of extracellular 
ATP catalyzed by CD39 and CD73 is the main pathway for adenosine formation 
in the tumor interstitium. Extracellular ATP and adenosine mold are both host 
and tumor responses. Depending on the activated specific receptor, extracel-
lular purines mediate host-side immunosuppression or immunostimulation and 
tumor-side growth stimulation or cytotoxicity. Recent developments in this area 
provide the key to deciphering this complex scenario, using the potential benefits of 
therapy. Preclinical data indicate that targeting the adenosine producing pathway or 
adenosinergic receptors attenuates immunosuppression and strongly inhibits tumor 
growth. On the other hand, the growth of experimental tumors is strongly inhibited 
by targeting the receptor of P2X7 ATP selective cancer and immune cells. The role 
of extracellular purines (purinergic signaling) acts in host-tumor interaction and 
highlights new treatment options from recent advances. There is now a consensus 
that ATP and adenine are the main components of tumor microenvironment 
(TME), in which TME affects tumor growth, immune cell functions and tumor-
host interaction in different ways. In view of the widespread observation that many 
malignant tumors overexpress several P1R or P2R subtypes, a simple approach 
would require targeting these receptors with selective receptors to suppress tumor 
receptor growth. On the same line of interference, the enzymes involved in the 
metabolism of extracellular nucleotides and nucleosides (CD39, CD73 and adenos-
ine deaminase) are viewed. Although the effectiveness of several simple preclinical 
models has been proven, this simple approach is clearly very pure. P1Rs, P2Rs and 
ATP/adenosine-disrupting enzymes are expressed together with host immunostim-
ulatory and stromal cells, which have very important functions for host integrated 
complex formation around the tumor. Careful selection of the candidate purinergic 
receptor in combination with modulators of extracellular adenosinergic pathways 
may allow inhibition of tumor cell growth and concomitantly increase the anti-
tumor host response. This anti-cancer agent will provide an additional powerful 
weapon for combinative treatments [15].
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Nucleotides and their receptors are emerging as potential actors in host-tumor 
interaction, such as new and important inflammatory and immune modulators. A 
large number of P2 and P1 receptors expressed by tumor and inflammatory cells 
exhibiting different ligand affinities for P2 and P1 receptor subtypes are modulated 
by local factors obtained from ectonucleotides and ADA on the nucleotide and 
adenosine concentration. In vivo data supports in vitro evidence that the reduction of 
the intratumour adenosine concentration and the targeting of the P2X7 receptor have 
a potent antitumor effect. Therefore, investigating the purinergic signaling in cancer 
opens promising perspectives for the development of innovative therapeutics [16].
Purinergic signaling has been focused on the tumor-associated immune 
response; nucleotides and nucleosides have strong direct effects on the tumor cells 
themselves. Stimulation of P2Y receptors (P2Y1 and P2Y2) promotes growth, there-
fore, depending on the expressed P2Y receptor subtypes, the accumulation of ATP 
in the tumor microenvironment is likely to promote tumor growth. In addition to 
P2Y receptors, P2X7 plays a role in tumor growth. It is a long-standing observation 
that most malignant tumors over-express P2X7 [17]. It is known that this receptor 
mediates a strong cytotoxic response [18]. Therefore, why a tumor should over-
express a “suicide” receptor is determined. However, cytotoxicity is most commonly 
triggered by pharmacological (i.e., near millimolar) ATP doses. In contrast, the 
activation of P2X7 by the endogenously released ATP produces a trophic, growth-
promoting effect [19].
Nucleotides and nucleosides in airway surface fluid regulate mucociliary clear-
ance (MCC) activities, the primary natural defense mechanism that removes for-
eign particles and pathogens from airway surfaces. These effects in the airways are 
mainly mediated by two purinergic receptor subtypes, the Gq-coupled ATP/UTP-
sensing P2Y2 receptor and the Gs-conjugated A2b adenosine receptor. Activation of 
the A2b receptor results in cyclic AMP-dependent activation of the Cın1 channel of 
the cystic fibrosis transmembrane regulator (CFTR) and stimulation of the ciliary 
pulse frequency. Agonist activation of the P2Y2 receptor promotes the inhibition of 
CFTR-dependent and CFTR-independent Cl secretion, ciliary beating and mucin 
secretion as well as Na+ absorption [20].
The phenomenon about the process reveals the participation of a biologi-
cal cascade. In this context, adenosine agonists and ATP-sensitive K+ channel 
(KATP) openers mimic some protective effects of the preconditioning process. 
Furthermore, these effects are reversed by adenosine antagonists and KATP block-
ers; this suggests that the release of adenosine and activation of KATP channels 
through adenosine Al receptors may constitute an early step in ischemic cerebral 
preconditioning [21].
Activation of the adenosine receptor, protein kinase C (PKC) and ATP-sensitive 
potassium (KATP) channel is known to trigger preconditioning. The data provides 
direct evidence that the KATP channel, rather than the adenosine receptor, is the 
effector downstream of PKC in initiating PKC-mediated preconditioning. Both 
the adenosine receptor and the KATP channel are required to promote the actual 
protective effect during continuous hypoxia [22]. The possibility of joining the bio-
logical stage of protective event involvement of adenosine A1 receptors and KATP 
channels, associated with cross-tolerance between KA-induced epileptic tolerance 
or KA-induced epilepsy and global ischemia, is evaluated [23].
2. Classification of the P1 and P2 receptors
The antinociceptive effects of adenosine via preconceptional P1 (A1) purinocep-
tors in the spinal cord and the pain-enhancing effects of adenosine with P1 (A2) 
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purinoceptors in the environment have shown great interest in the development of 
P1 agonists and antagonists and P2X antagonists as potential analgesic drugs [24].
Purinergic receptors are divided into adenosine receptors (P1) and nucleotide 
receptors (P2). The receptors for nucleotides are also divided into two main groups: 
ligand-gated ion channels (P2X) and G-protein-associated receptors (P2Y). Upon 
vascular injury, platelets are collected at the site of injury to form a hemostatic plug. 
Abnormal activation of platelets leads to thrombosis, resulting in greater paralysis and 
a risk of myocardial infarction. The importance of ADP in hemostasis and thrombosis 
greatly underscores the significance of understanding the function of these receptors 
that would enable development of potent and safe antithrombotic drugs. This makes 
ADP receptors antagonize or interfere. Purinergic receptors are shown in Figure 2.
The molecular mechanisms of platelet activation caused by ADP are now evi-
dent. The separation and interactions of a unique P2T receptor concept into three 
components (i.e., P2Y1, P2Y12 and P2X1 receptors) helped to explain the intracel-
lular and physiological effects of ADP on platelets. The interaction of signaling 
events under P2Y1 and P2Y12 receptors is a new physiological response and may be 
a general mechanism of α1bβ3 integrin activation by all physiological agonists. It is 
also shown to be a mechanism of activation for another platelet integrin αVβ3 [25].
Results from this observation include a fourth P2 receptor subtype on platelets 
and P2Y12 receptor binding to other G proteins. The precise signaling mechanisms 
and pathways mediated by these three P2 receptor subtypes will provide a bet-
ter understanding of the molecular mechanisms of ADP-mediated physiological 
responses in platelets and, in general, agonist-induced platelet activation [26].
Two types of purinergic receptors were distinguished: P1 purines are the most 
sensitive to adenosine and AMP, competitively blocked by methylxanthines; P2 puri-
noceptors are most sensitive to ATP and ADP, and quinidine is blocked (although not 
competitive) by 2-substituted imidazoline, 2,2′-pyridylisatogen and apamine, and 
their use leads to the production of prostaglandins. Adenosine reduces the heart rate 
and contraction force of the atrium and the ventricles of most species. It disrupts con-
duction in the atrioventricular node and has a particularly strong effect on the sino-
atrial pacemaker. These effects are blocked by methylxanthines and strengthened by 
dipyridamole. ATP is also a contractility potent inhibitor of the heart of most species 
but initially has a positive inotropic effect on the frog’s heart, followed by inhibition 
(possibly due to adenosine after rapid disintegration of ATP). Adenyl compounds 
allow the expansion of coronary vessels. ATP and ADP are the most potent, and ade-
nosine and AMP are partially about 25%, whereas inosine, adenine and hypoxanthine 
are almost inactive. Adenosine acts on the presynaptic P1 purinoceptors, reducing the 
release of noradrenaline and acetylcholine from the adrenergic and cholinergic nerve 
terminals. These effects are blocked by methylxanthines. Adenosine probably induces 
Figure 2. 
Purinergic receptors [2].
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adenylate cyclase in the three main regions of the heart (i.e., heart muscle, vascular 
smooth muscle and nerve terminals), causing changes in cAMP accumulation and a 
reduction in Ca2+ flux. The mechanism of action of ATP is unknown. There is strong 
evidence for a physiological role for adenyl compounds in the regulation of coronary 
blood flow. The concentration of adenosine, ischemia-induced ATPs acting on the P1 
purinorecceptors, acting on vasoconstriction of vasodilatation from cardiac hyperac-
tivity, may be increased by the release of intranural purinergic nerves and acting on 
P2 purinoseptors. Some purinergic nerves affect sinoatrial pacemaker activity, and 
adenosine may be a physiological presynaptic modulator of cardiothoracic activity of 
both adrenergic and cholinergic nerves [27]. ATP and other purine nucleotides and 
nucleosides have strong regulatory (similar to neurotransmitter) effects attributed 
to interaction with a specific plasma membrane receptor 1. To date, receptor mecha-
nisms underlying purinergic activation have been poorly characterized. One problem 
was the variability of excited effects in different tissues [28]. It was suggested that 
most of the effects could be explained if two different receptors, called P1 and P2, 
have different properties for agonists and antagonists. The receptor mechanisms in 
the parotid gland have been extensively studied. ATP causes a significant increase in 
membrane conductivity, radioactive Rb flow and amylase secretion. The effects of 
ATP are similar to those induced by acetylcholine (ACh) and α-adrenergic agonists 
but are still present when cholinergic and adrenergic blocking agents are used. The 
latency and return potential of the effects induced by ATP can be compared to those 
of autonomic agonists. General structures of different classes of P2X7 antagonists are 
shown in Figures 3 and 4.
Since the sequence of action of the nucleotide sequence was ATP > ADP > AMP, 
adenosine had no effect, and the response could be blocked by quinidine, but not by 
theophylline [29]. Activation of P2Y1 and P2Y12 receptors by secreted ADP induced 
by agonists such as thrombin, thromboxane and collagen is the main mechanism of 
platelet activation. P2X1 receptors also contribute to the change of platelet shape 
and enhance calcium mobilization. Cloning of the P2Y12 receptor and knockout in 
Figure 3. 
General structures of different classes of P2X7 antagonists [2].
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subsequent mice promises a better understanding of downstream signaling events. 
Interestingly, mouse platelets missing from the P2Y1 receptor may enter partial 
deposition with high ADP concentrations [30]. Chemical structures of literature 
P2X7 receptor antagonists are shown in Figure 5.
Figure 5. 
Chemical structures of literature P2X7 receptor antagonists [2].
Figure 4. 
General structures of different classes of P2X7 antagonists [2].
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3. Functions of the purinergic receptors in metabolism
3.1 Functions of the purinergic receptors in the cardiac system
Multiple P2 receptor subtypes are located in the microglia pain paths as both 
initiator and modulator. Activation of homomeric P2X3 receptors probably contrib-
utes to some aspects of acute nociception and acute inflammatory pain. In contrast, 
activation of heteromeric P2X23 receptors appears to modulate the duration of noci-
ceptive sensitivity associated with nerve injury or chronic inflammation. In addition, 
P2X4, P2X7 and P2Y12 receptors can serve to protect nociceptive sensitivity through 
sensitization of other nociceptive receptors such as TRPV1 channels or complex 
neural-glial cell interactions under conditions of continuous nociceptive activation 
on microglia. P2X3, P2X4, P2X7 and P2Y12 receptor antagonists are used for neu-
ropathic pain. The study is being investigated for orally biologically available P2X3, 
P2X23, P2X4, P2X7 and P2Y12 receptor antagonists with molecules able to cross the 
blood-brain barrier and not be degraded in vivo during the pain treatment. In par-
ticular, the P2X7 receptor has become the main target for inflammatory neuropathic 
pain and a number of selective P2X7 receptor antagonists have been developed. 
There is also a review describing the recent advances in the development of adenos-
ine receptor ligands as anti-inflammatory drugs [31]. Other therapeutic approaches, 
including the development of agents that control the expression of receptors and 
the selective inhibition of known ectonucleotides, as well as the development of 
agents that prevent the degradation of ATP, are considered. It is also expected the 
mechanisms underlying the transport of ATP to be understood, although it is clear 
that many different cell types secrete physiologically to ATP in response to mechani-
cal deterioration, hypoxia and various agents. Hopefully, when this becomes clearer, 
agents will be developed that will increase or enhance the release of ATP, another 
useful pathway that stands out as a therapeutic strategy. In this context A134757, a 
novel adenosine kinase (AK) inhibitor, alleviated tactile allodynia by means of spinal 
action sites in peripheral nerve injury rats and added increased evidence that EC 
inhibitors may be useful analgesic agents [32]. Furthermore, human macrophages 
express purinic receptors with the rIFN-an modulated P2Z subtype [33].
Purinergic receptor expression in human dendritic cells is associated with the 
pharmacological and biochemical evidence that immature and mature cells express 
P2Y and P2X subtypes associated with intracellular Ca2+, membrane depolariza-
tion and secretion of inflammatory cytokines. ATP-activated Ca2+ mobilization is 
biphasic, which is rapidly released from intracellular stores and releases a second 
delayed flow in the plasma membrane. Prolonged exposure to ATP was toxic to 
dendritic cells (swollen, lost from typical dendrites, phase lents were exhibited, 
separated from substrate, and eventually died). These changes strongly elicited the 
expression of the cytotoxic receptor P2X7 as confirmed by the ability of dendritic 
cells to become permeable to membrane impermeable dyes such as Lucifer’s yellow 
or ethidium bromide. P2X7 receptor ligand 2 isolation, 3 z-(4-benzoylbenzoyl) 
-ATP was a better agonist, followed by an increase in Ca2+ and ATP-induced plasma 
membrane depolarization. ATP oxidized and the P2X7 antagonist KN-62, a covalent 
blocker of P2X receptors, inhibited both permeabilization and ATP-induced Ca 
2+ changes. The following purinoceptors were expressed by immature and mature 
dendritic cells: P2Y1, P2Y2, P2Y5 and P2Y11 and P2X1, P2X4 and P2X7. Finally, 
stimulation of matured cells with LPS by ATP induced IL-1 and TNF-α release. 
Therefore, these receptors can provide a new way of modulating dendritic cell 
function [34]. Glutamate is a well-known excitotoxic agent that can lead neurons 
and astrocytes to death when it is present as the primary mediator of stimulatory 
neurotransmission in the central nervous system and in extracellular milieu [35]. 
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The ability to release this transmitter demonstrates the direct involvement of astro-
cytes in glutamatergic neuronal transmission and in the excitotoxic effect of gluta-
mate [36]. Although this last problem has been proven, a large number of evidence 
suggests that astrocyte-derived glutamate has complex effects on neurons that play 
a modulator role in synaptic transmission. In the hippocampus, it modulates the 
excitability of the interneurons and strengthens the inhibitory transmission; it also 
acts on the stimulating axon terminals of the CA1 region to increase the probability 
of spontaneous glutamate release [37]. At the same time, astrocytic glutamate has 
a direct effect on hippocampal pyramidal neurons by activating extra-synaptic 
NMDARs and triggering episodic inward currents (SICs) characterized by slow 
kinetics. Interestingly, this NMDAR response may occur simultaneously in many 
CA1 neurons, and this increases the likelihood of synergistic neuronal activity [38].
The results show that activation of different purinergic receptors in the hip-
pocampus are mediated by two types of glutamate release, each of which induces 
a different response in CA1 pyramidal neurons. In the first release, P2X7R is 
not included. This release of glutamate mediated for astrocytes evokes transient 
NMDAR-mediated responses (SICs) in CA1 pyramidal neurons, which represent a 
sign of astrocyte-neuron communication. In the second type of release, a receptor 
similar to P2X7 may be included. This phenomenon is enhanced under nonphysi-
ological conditions, increasing the likelihood of contributing to the excitotoxic 
effect of glutamate in the brain.
The presence of a non-cholinergic, non-adrenergic component in the vertebrate 
autonomic nervous system is now well established. Evidences that ATP is a donor 
released from some of these nerves include
a. synthesis and storage of ATP
b. release of ATP from nerves when stimulated
c. externally applied ATP mimicking the action of the nerve-secreting donor
d. the presence of enzymes that inactivate ATP
e. exogenously administered ATP and drugs that produce similar blocking or 
enhancing effects on response to nerve stimulation.
A basis for distinguishing two types of purinergic receptors has been proposed 
based on four criteria: relative forces of agonists, competitive antagonists, changes 
in cAMP levels and stimulation of prostaglandin synthesis. P1 purinoceptors 
are therefore most susceptible to adenosine and are blocked in competition with 
methylxanthines, and their use leads to changes in cAMP accumulation; P2 puri-
noceptors are most sensitive to ATP, but, although not competitive, quinidine is 
blocked by 2-substituted imidazolines, 2,2′-pyridylisatogen and apamine, and their 
use leads to prostaglandin production. P2 purinoceptors mediate the response of 
smooth muscle to ATP released from purinergic nerves, while P1 purinogens medi-
ate the presynaptic effects of adenosine on adrenergic, cholinergic and purinergic 
nerve terminals [39].
The discovery of a P2X purinoceptor (a ligand-gated ion channel triggered by 
ATP) that is selectively expressed by small-diameter sensory neurons has led to the 
investigation of ATP sources involved in the initiation of different types of nocicep-
tion and pain types including sympathetic nerves, endothelial cells and tumor cells. 
To a lesser extent, ATP stimulates the sensory nerve endings in the skin, causes 
severe pain, and causes a significant increase in discharge from sensory neurons. 
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The molecular structure of the PZX3 purinepeptor is associated with the nociceptor 
and is associated with the search for the PZX3 purinoceptor to identify selective 
antagonists (Xenopus oocytes and/or transfected cells can be expressed herein).
When defined, such antagonists can be tested in vitro models of different types 
of pain. It is clear that PZX3 purine receptors are not the only receptors involved 
in pain, so a synergy with receptors for other pain-modulating agents (such as 
bradykinin, histamine and S-hydroxytryptamine) should be investigated. ATP acts 
on receptors on sensory nerve terminals; it has been reported that ATP acts on the 
dorsal horn neurons in the spinal cord after release from a subpopulation of small 
primary afferent nerves in the pain pathways.
There are multiple P2 receptor-mediated mechanisms in which ATP can alter 
nociceptive sensitivity following tissue damage. Evidence from various experi-
mental strategies, including genetic degradation studies and the development of 
selective antagonists, modulates pain in the activation of P2X receptor subtypes, 
including P2X3, P2X2 / 3, P2X4 and P2X7 and P2Y (eg P2Y2) receptors. For 
example, administration of A-317491, a selective P2X3 antagonist, has been shown 
to effectively block both hyperalgesia and allodynia in different pathological painful 
animal models. Antisense oligonucleotides administered intrathecally to target 
P2X4 receptors reduce tactile allodynia following nerve damage. Selective antago-
nists for the P2X7 receptor also reduce sensitivity in animal models of inflammatory 
and neuropathic pain; This provides evidence that purinergic glial nerve interac-
tions are important modulators of harmful sensory neurotransmission. In addition, 
activation of P2Y2 receptors leads to the planning of polmodal transient receptor 
potential-1 receptors. Thus, ATP acts either directly on neurons (P2X3, P2X2/3 
and P2Y receptors) or directly on multiple purinergic receptors that are indirectly 
affected by neural-glial cell interactions (P2X4 and P2X7 receptors). The develop-
ment of selective antagonists for some of these P2 receptors has greatly helped to 
investigate the nociceptive role of ATP. This perspective highlights some of the 
recent advances to identify selective P2 receptor ligands that enhance the investiga-
tion of ATP-related pain sensitivity modulation [40].
3.2 Function of the purinergic receptors in the retina
P2X receptors are ligand-gated ion channels which are activated by adenosine tri-
phosphate and expressed in a wide variety of tissues. The expression of various types 
of purinergic P2X receptors is shown in defined retinal ganglion cells (RGCs) of 
the adult rat retinas. The single-cell reverse transcription polymerase chain reaction 
(SC-RT-PCR) resulted in a positive amplification signal for all P2X receptor subunit 
mRNAs studied (P2X3X5, P2X7). Immunohistochemistry with antibodies specific 
to the P2X3,4 receptor subunit showed the label of neurons in the ganglion cell layer 
and internal nuclear layer. The data suggest that extracellular ATP is directly effec-
tive on RGCs through several types of P2X receptors and may provide neuromodula-
tory effects in the retinal information processing [41]. For example, in the retina, 
glutamate release from acetamides modulates the spike activity in ganglion cell that 
is most likely driven by mild stimulation with a presynaptic action [42].
3.3. Function of the purinergic receptors in the heart
Both the adenosine receptor and the ATP-responsive K (KATP) channel medi-
ate the intact heart-protective effect of ischemic preconditioning. The data [43] 
provides direct evidence that the myositis KATP channel is effective downstream 
of the adenosine Al receptor in mediating direct preconditioning of cardiac 
myocytes.
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A study by Liang and Gross [44] showed that the functional opioid receptors 
were found in chick cardiac ventricular myocytes. The activation of the receptors 
by the nonselective opioid receptor agonist morphine can result in a PC-like effect. 
The protective effect of morphine in myocytes was probably mediated by the 
activation of the K1 (KATP) channel, which is sensitive to mitochondrial origin, 
ATP. However, the identity of the specific subtype of the said opioid receptor and 
the signaling pathway for mediating cardioprotective effect to the mitochondrial 
KATP channel from the receptor is unknown [45].
3.4 Function of the purinergic receptors in cancer
Reports documenting the activity of convergent ATP and its metabolites on can-
cer growth demonstrate a clear issue of how we can benefit from purifying cancer 
from purinergic signaling. Schematically, two paths are possible for the host and/
or the tumor side to interfere. The available evidence in several experimental tumor 
models clearly demonstrates that decreasing adenosine concentration inhibits 
tumor progression and prevents metastasis [46]. The concentration of adenosine 
in the tumor interstitium can be reduced by downregulation of CD39 and/or CD73 
or by upregulation of CD26. Alternatively, ADA may be targeted to the tumor as a 
PEG-ADA conjugate [47]. Also, on the host side, the beneficial effect of ATP release 
is demonstrated by the ability to activate the P2X7/inflammatory axis including the 
immune cells [48]. Thus, a pharmacological strategy may be based on the adminis-
tration of CD39 inhibitors with double beneficial effect to maintain adequate levels 
of ATP for immunostimulation and to prevent adenosine accumulation.
When the use of purinergic receptors as a novel treatment for non-melanoma 
skin cancers is investigated; purinergic receptors binding adenosine-5′-triphosphate 
are expressed in human cutaneous keratinocytes. Previous studies in rat and human 
epidermis have proposed functional roles for purinergic receptors in the regulation 
of proliferation, differentiation and apoptosis. Immunohistochemical analysis of 
frozen sections in human basal cell carcinomas and squamous cell carcinomas for 
P2X5, P2X7, P2Y1, P2Y2 and P2Y4 receptors was performed with detailed analysis of 
the archive material of tumor subtypes in paraffin sections. Functional studies were 
performed using the human cutaneous squamous cell carcinoma cell line (A431), 
where purinergic receptor subtype agonists were applied to cells and changes in cell 
number were measured by a colorimetric assay. P2X5 and P2Y2 receptors have been 
extensively expressed in basal cell carcinomas and squamous cell carcinomas. P2X7 
receptors were expressed in the necrotic center of nodular basal cell carcinomas and 
in apoptotic cells in superficial multifocal and infiltrative basal cell carcinomas and 
squamous cell carcinomas. P2Y1 receptors were expressed only in tumors sur-
rounding the stroma. P2Y4 receptors were found in basal cell carcinomas but not in 
squamous cell carcinomas. P2X5 receptors appear to be associated with differentia-
tion. P2X7 receptor agonist benzoylbenzoyl-adenosine 5 accordingly-triphosphate 
and high concentrations of adenosine 5 (-tophosphate (1000) 5000 concentM) 
lead to a significant decrease in A431 cell number (p <0.001), while P2Y2 receptor 
agonist uridine 5 triphosphate significantly induced proliferation (p. <0.001). It is 
shown that non-melanoma skin cancers express functional purinergic receptors and 
significantly reduce in vitro cell numbers of P2X7 receptor agonists [49].
3.5 Function of the purinergic receptors in the fetal epidermis
It is expressed the expression of P2X5, P2X7, P2Y1 and P2Y2 receptor subtypes in 
the 8–11-week human fetal epidermis associated with proliferative proliferation mark-
ers (proliferative cell nuclear antigen (PCNA) and Ki-67), keratinocyte differentiation 
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(cytokeratin K10 and involucrin) and apoptosis marker (TdT-mediated dUTP-biotin 
nick end labeling (TUNEL) and anti-caspase-3). Immunohistochemistry showed that 
each of the four receptors was expressed in spatially distinct regions of the developing 
epidermis: the P2Y1 receptors were found in the basal layer, the P2X5 receptors were 
found mainly in the basal and intermediate layers, and both P2Y2 and P2X7 receptors 
were in the periderm. Colocalization assays have proposed different functional roles 
for these receptors. In fetal keratinocytes positive for PCY and Ki-67, P2Y1 receptors 
were found, indicating a role in proliferation. Double-labeled P2X5 receptors with 
differentiated fetal keratinocytes, which are positive for cytokeratin K10, show that 
they play a role in differentiation. It was expressed in periderm cells, positive for P2X7 
receptors collozed with anti-caspase-3 antibody and also positive for TUNEL, suggest-
ing a role in periderm cell apoptosis. P2Y2 receptors have been found only in periderm 
cells and may play a role in the release of chloride and fluid into the amniotic fluid [50].
3.6 Function of the purinergic receptors in the kidney
Autocrine and paracrine signals in the kidney nephron have been a widely 
used hypothesis for decades. The lumen of the nephron is an ideal autocrine and 
paracrine signal microenvironment. Any agonist released from the glomerulus or 
released in the proximal tubule or other proximal segments is then retained in the 
nephron lumen and is present to interact with the lumen receptors. Similar signals 
in the renal interstitium are also possible and possible. In fact, for many autocrine 
and paracrine agonists, the receptors have been characterized on the lumen mem-
brane and serosal membrane of many nephron segments. An important autocrine 
and paracrine agonist family in the kidneys are purinergic agonists. In addition to 
extracellular ATP, metabolites (ADP, 5′-AMP and adenosine) are released by renal 
epithelial cells. These compounds are also freely filtered in the glomerulus and are 
in the final urine. ATP and adenosine receptors are also expressed on the lumen and 
serosal side of many nephron segments. This review discusses purinergic signaling 
by nucleotide agonists from ATP release to ATP receptors to extracellular ATP medi-
ated effects in renal epithelial function. These themes are the areas in which our 
Figure 6. 
P2X7 receptor and diseases [2].
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laboratory focuses on normal and diseased epithelial cells in normal and polycystic 
kidneys and other tissues. The physiological roles of extracellular purinergic signals 
in the kidney and other tissues began to emerge [51]. P2X7 receptor and diseases are 
shown in Figure 6.
4. Conclusions
Purinergic receptors are a family of newly characterized plasma membrane mol-
ecules in the field of signaling. As a result of many scientific studies, these receptors 
have been associated with many cellular functions including vascular reactivity, 
apoptosis and cytokine secretion; learning and memory, locomotor and feeding 
behavior and proliferation and migration of sleep neural stem cells. Activation of 
these receptors is partly due to the release of ATP (or UTP) from the cells, usually 
in the determination of cellular damage. Further studies are needed to better define 
the functions of purinergic receptors and to better understand the effect of extra-
cellular micro-environment on their functions.
Author details
Eren Sarikaya
Van Yuzuncu Yil University, Van, Turkey
*Address all correspondence to: erensarikaya1@gmail.com
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Functions of Purinergic Receptors
DOI: http://dx.doi.org/10.5772/intechopen.88251
References
[1] North RA, Barnard EA. Nucleotide 
receptors. Current Opinion in 
Neurobiology. 1997;7(3):346-357. DOI: 
10.1016/S0959-4388(97)80062-1. PMID: 
9232809
[2] Mehta N, Kaur M, Singh M, Chand S, 
Vyas B, Silakari P, et al. Purinergic 
receptor P2X₇: A novel target for anti-
inflammatory therapy. Bioorganic & 
Medicinal Chemistry. 2014;22(1):54-88. 
DOI: 10.1016/j.bmc.2013.10.054. PMID: 
24314880
[3] Boyer JL, Lazarowski ER, Chen XH, 
Harden TK. Identification of a P2Y-
purinergic receptor that inhibits adenylyl 
cyclase. The Journal of Pharmacology 
and Experimental Therapeutics. 
1993;267(3):1140-1146. PMID: 8263774
[4] Lohmann K. Über die 
pyrophosphatfraktion im muskel. Die 
Naturwissenschaften. 1929;17(31): 
624-625. DOI: 10.1007/BF01506215
[5] Abbracchio MP, Burnstock G, 
Verkhratsky A, Zimmermann H. 
Purinergic signalling in the nervous 
system: An overview. Trends in 
Neurosciences. 2009;32(1):19-29. DOI: 
10.1016/j.tins.2008.10.001. PMID: 
19008000
[6] Dubyak GR. Signal transduction 
by P2-purinergic receptors for 
extracellular ATP. American Journal of 
Respiratory Cell and Molecular Biology. 
1991;4(4):295-300. DOI: 10.1165/
ajrcmb/4.4.295. PMID: 1707633
[7] Dubyak GR, El-Moatassim C. Signal 
transduction via P2-purinergic receptors 
for extracellular ATP and other 
nucleotides. The American Journal of 
Physiology. 1993;265(3 Pt 1): 
C577-C606. DOI: 10.1152/
ajpcell.1993.265.3.C577. PMID: 8214015
[8] Scheepers A, Joost HG, 
Schürmann A. The glucose transporter 
families SGLT and GLUT: Molecular 
basis of normal and aberrant function. 
JPEN Journal of Parenteral and Enteral 
Nutrition. 2004;28(5):364-371. DOI: 
10.1177/0148607104028005364. PMID: 
15449578
[9] Cartier EA, Conti LR, 
Vandenberg CA, Shyng SL. Defective 
trafficking and function of KATP 
channels caused by a sulfonylurea 
receptor 1 mutation associated 
with persistent hyperinsulinemic 
hypoglycemia of infancy. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2001;98(5):2882-2887. DOI: 10.1073/
pnas.051499698. PMID: 11226335
[10] Yee KK, Sukumaran SK, Kotha R, 
Gilbertson TA, Margolskee RF. Glucose 
transporters and ATP-gated K+ (KATP) 
metabolic sensors are present in type 
1 taste receptor 3 (T1r3)-expressing 
taste cells. Proceedings of the National 
Academy of Sciences of the United 
States of America. 2011;108(13):5431-
5436. DOI: 10.1073/pnas.1100495108. 
PMID: 21383163
[11] Kirsch GE, Codina J, Birnbaumer L, 
Brown AM. Coupling of ATP-sensitive 
K+ channels to A1 receptors by G 
proteins in rat ventricular myocytes. 
The American Journal of Physiology. 
1990;259(3 Pt 2):H820-H826. DOI: 
10.1152/ajpheart.1990.259.3.H820. 
PMID: 2118729
[12] Bryan J, Crane A, Vila-Carriles WH, 
Babenko AP, Aguilar-Bryan L. Insulin 
secretagogues, sulfonylurea 
receptors and K(ATP) channels. 
Current Pharmaceutical Design. 
2005;11(21):2699-2716. DOI: 
10.2174/1381612054546879. PMID: 
16101450
[13] Van Winkle DM, Chien GL,  
Wolff RA, Soifer BE, Kuzume K, 
Davis RF. Cardioprotection provided 
